Three-year, team-science grants for closely integrated clinical and translational projects in HER2-mutant lung cancer; proposals must involve patients, include a patient advocate, and preferably be associated with or lead to a clinical trial.
Eligibility Criteria:
-
Faculty-level team leaders with complementary expertise; designate one PI for administrative leadership. Teams may span multiple (including international) institutions; applicants can hold any residency/citizenship status. Must include a patient/patient advocate with a role in study design. Applicants may not be current LCRF grantees and may submit only one LCRF application per cycle. Senior investigators (>5 years past first faculty appointment) must show independent programs.
Funding Details:
-
Up to USD 1,500,000 total over 3 years (USD 500,000/year). Up to 10% indirect costs allowed; travel/publication costs permitted; equipment must be limited and directly applicable. Salary support has no fixed cap but requests >20% of total must be explicitly justified. Funds are released in three installments tied to reporting.
Deadline:
-
September 30, 2025.
-
Full proposals due January 6, 2026; finalist presentations March 2026; awards announced May 2026.
Where to Go for Further Information:
-
Apply via ProposalCentral, search “2025 LCRF | Boehringer Ingelheim Team Science Award on Innovative Approaches Toward the Treatment of HER2-Driven Lung Cancer.”
-
Program questions: [email protected].